Published 16 hours ago • loading... • Updated 16 hours ago

Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia

Zhejiang Doer Biologics Co., Ltd. Has completed enrollment in its Phase 2 clinical study of DR10624 for treating severe hypertriglyceridemia, with 79 patients enrolled.
The study, titled DR10624-201, is randomized, placebo-controlled, and will evaluate the efficacy and safety of DR10624, which targets FGF21R, GCGR, and GLP-1R over 12 weeks.
Patients enrolled have fasting triglyceride levels greater than or equal to 5.65 mmol/L .
Patients with severe hypertriglyceridemia face risks of acute pancreatitis and cardiovascular disease, increasing hospitalization and death risks.

Insights by Ground AI

Does this summary seem wrong?

49 Articles

All

Left

Center

Right

Buffalo News

+48 Reposted by 48 other sources

Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624 for Treatment of Severe Hypertriglyceridemia

HANGZHOU, China, March 9, 2025 /PRNewswire/ -- Zhejiang Doer Biologics Co., Ltd. ("Doer Bio"), a clinical stage biopharmaceutical company developing innovative biotherapeutics for metabolic diseases and cancers, today announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor…

16 hours ago·Buffalo, United States

Read Full Article

Buffalo News